Drug Profile
Research programme: cancer and sepsis therapeutics - TaiRx
Alternative Names: EFP 306; TRX 306; TRX 606Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator TaiRx
- Class Anti-infectives; Antineoplastics
- Mechanism of Action Growth inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Sepsis
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for preclinical development in Cancer in Taiwan (PO)
- 28 Aug 2019 No recent reports of development identified for preclinical development in Sepsis(Adjunctive treatment) in Taiwan (Parenteral, Injection)
- 29 Jul 2015 Preclinical trials in Cancer in Taiwan before July 2015 (PO)